Torrent Pharmaceuticals Issues ₹300 Crore Commercial Papers

Ahmedabad-based Torrent Pharmaceuticals Ltd has issued commercial papers (CPs) worth ₹300 crore on March 25, 2025, as per a regulatory filing. The issuance is part of the company’s strategy to manage working capital and fund operational needs efficiently.

Details of the Commercial Paper Issuance

The commercial papers, which are unsecured, carry a discount rate of 7.13% per annum and have a tenure of 90 days, with a maturity date set for June 23, 2025. These instruments, commonly traded in the secondary market, will be available for transactions through the National Stock Exchange of India (NSE).

As per the filing, the CPs are issued at a discount, meaning investors will receive the face value upon maturity. There are no special rights or privileges attached to these instruments.

Torrent Pharma Maintains a Strong Credit Record

Torrent Pharmaceuticals has confirmed that there have been no defaults or delays in payments related to interest or principal, reinforcing its strong financial track record.

As a key player in India’s pharmaceutical sector, Torrent Pharma continues to leverage short-term debt instruments like commercial papers to optimize liquidity and meet short-term financial obligations.

The issuance aligns with the company’s broader financial strategy, ensuring smooth cash flow management and operational efficiency in a dynamic market environment.

Stock Performance

On March 25, 2025, Torrent Pharma share price ended 0.60% higher at ₹3,279.30. Torrent Pharma’s share price reached a 52-week high of ₹3,589.95, and a 52-week low of ₹2,508.65. As per BSE, the total traded volume for the stock stood at 1,879 shares with a turnover of ₹60.65 lakhs.

At the current price, Torrent Pharma shares are trading at a price-to-earnings (P/E) ratio of 59.98x, based on its trailing 12-month earnings per share (EPS) of ₹53.89, and a price-to-book (P/B) ratio of 14.54, according to exchange data.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.